The role of interferon-γ, nitric oxide and lipopolysaccharide in intestinal graft-versus-host disease developing in F1-hybrid mice

Immunology

Volumn 109, Issue 3, 2003, Pages 440-449

  Ellison, Cynthia A ^a   Natuik, Shannon A ^a   McIntosh, Alan R ^a   Scully, Sheila A ^b   Danilenko, Dimitry M ^b   Gartner, John G ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENDOTOXEMIA; FEMALE; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HYBRID; INTESTINE CRYPT; INTESTINE EPITHELIUM CELL; KNOCKOUT MOUSE; LETHALITY; LYMPHOID CELL; MOUSE; NONHUMAN; ORGAN DONOR; PATHOGENESIS; PRIORITY JOURNAL; SERUM; WILD TYPE;

ACUTE DISEASE; ANIMALS; APOPTOSIS; CROSSES, GENETIC; EPITHELIAL CELLS; FEMALE; GRAFT VS HOST DISEASE; INTERFERON TYPE II; INTESTINAL MUCOSA; JEJUNUM; LIPOPOLYSACCHARIDES; LYMPHOCYTE TRANSFUSION; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RNA, MESSENGER;

EID: 0038466071     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2003.01663.x     Document Type: Article

References (33)

1. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987; 166:1280-9.
2. Holler E, Kolb HJ, Hintermeier-Knabe R, Mittermuller J, Thierfelder S, Kaul M, Wilmanns W. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 1993; 25:1234-6.
3. Howard JG, Woodruff MFA. Effect of the graft-versus-host reaction on the immunological responsiveness of the mouse. Proc R Soc Lond 1961; 154:532-9.
4. Blaese M, Martinez C, Good RA. Immunological incompetence of immunologically runted animals. J Exp Med 1964; 119:211-24.
5. Lapp WS, Ghayur T, Mendes M, Seddik M, Seemayer TA. The functional and histological basis for graft-versus-host-induced immunosuppression. Immunol Rev 1985; 88:107-33.
6. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324:667-74.
7. Piguet PF, Grau GE, Collart MA, Vassalli P, Kapanci Y. Pneumopathies of the graft-versus-host reaction. Alveolitis associated with an increased level of tumor necrosis factor mRNA and chronic interstitial pneumonitis. Lab Invest 1989; 61:37-45.
8. Jones JM, Wilson R, Bealmear PM. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat Res 1971; 45:577-88.
9. Beelen DW, Elmaagacli A, Muller KD, Hirche H, Schaefer UW. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93:3267-75.
10. Beelen DW, Haralambie E, Brandt H, et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 1992; 80:2668-76.
11. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175:405-13.
12. Fowler DH, Kurasawa K, Husebekk A, Cohen PA, Gress RE. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. J Immunol 1994; 152:1004-13.
13. Price KS, Nestel FP, Lapp WS. Progressive accumulation of bacterial lipopolysaccharide in vivo during murine acute graft-versus-host disease. Scand J Immunol 1997; 45:294-300.
14. Nestel F, Kichian KY-TK, Desbarats J, Price K, Ponka P, Lapp W, Seemayer T. The role of endotoxin in the pathogenesis of acute graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-Vs-Host Disease. New York: Marcel Dekker, 1997:501-23.
15. Ellison CA, Amadeo RJ, Gartner JG. GVHD-associated enteropathy and endotoxemia in F1-hybrid recipients of NK1.1-depleted grafts. Scand J Immunol 2001; 54:375-82.
16. Koltun WA, Bloomer MM, Colony P, Kauffman GL. Increased intestinal permeability in rats with graft versus host disease. Gut 1996; 39:291-8.
17. Stuber E, Buschenfeld A, von Freier A, Arendt T, Folsch UR. Intestinal crypt cell apoptosis in murine acute graft versus host disease is mediated by tumour necrosis factor alpha and not by the FasL-Fas interaction: effect of pentoxifylline on the development of mucosal atrophy. Gut 1999; 45:229-35.
18. Brown GR, Lee E, Thiele DL. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J → C57BL/6J x bml2), F1 mice. J Immunol 2002; 168:3065-71.
19. Brown GR, Lindberg G, Meddings J, Silva M, Beutler B, Thiele D. Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease. Gastroenterology 1999; 116:593-601.
20. Garside P, Hutton AK, Severn A, Liew FY, Mowat AM. Nitric oxide mediates intestinal pathology in graft-vs.-host disease. Eur J Immunol 1992; 22:2141-5.
21. Mowat AM. Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology 1989; 68:18-23.
22. Ellison CA, Fischer JM, HayGlass KT, Gartner JG. Murine graft-versus-host disease in an F1-hybrid model using IFN-gamma gene knockout donors. J Immunol 1998; 161:631-40.
23. Hoffman RA, Nussler NC, Gleixner SL, Zhang G, Ford HR, Langrehr JM, Demetris AJ, Simmons RL. Attenuation of lethal graft-versus-host disease by inhibition of nitric oxide synthase. Transplantation 1997; 63:94-100.
24. Langrehr JM, Machens C, Zill E, Leder K, Nussler A, Hoffman R, Neuhaus P. Bacterial translocation during graft-versus-host disease after small bowel transplantation is reduced following inhibition of inducible nitric oxide synthesis. Transplantation 2000; 69:2415-21.
25. Gartner JG, Merry AC, Smith CI. An analysis of pulmonary natural killer cell activity in F1-hybrid mice with acute graft-versus-host reactions. Transplantation 1988; 46:879-86.
26. Wang HH, McIntosh AR, Hasinoff BB, Rector ES, Ahmed N, Nance DM, Orr FW. B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: a natural hepatic defense against metastasis. Cancer Res 2000; 60:5862-9.
27. Moore WM, Webber RK, Jerome GM, Tjoeng FS, Misko TP, Currie MG. L-N6-(1-iminoethyl) lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem 1994; 37:3886-8.
28. Stenger S, Thuring H, Rollinghoff M, Manning P, Bogdan C. L-N6-(1-iminoethyl)-lysine potently inhibits inducible nitric oxide synthase and is superior to NG-monomethyl-arginine in vitro and in vivo. Eur J Pharmacol 1995; 294:703-12.
29. Wall AJ, Rosenberg JL, Reilly RW. Small intestinal injury in the immunologically runted mouse: morphologic and autoradiographic studies. J Lab Clin Med 1971; 78:833-4.
30. Mowat AM. Intestinal graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-Vs-Host Disease. New York: Marcel Dekker, 1997:337-84.
31. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90:3204-13.
32. Crouser ED, Julian MW, Weinstein DM, Fahy RJ, Bauer JA. Endotoxin-induced ileal mucosal injury and nitric oxide dysregulation are temporally dissociated. Am J Respir Crit Care Med 2000; 161:1705-12.
33. Lamarque D, Moran AP, Szepes Z, Delchier JC, Whittle BJ. Cytotoxicity associated with induction of nitric oxide synthase in rat duodenal epithelial cells in vivo by lipopolysaccharide of Helicobacter pylori: inhibition by superoxide dismutase. Br J Pharmacol 2000; 130:1531-8.